Stephanie Graff, MD, FACP

Dr. Graff is the Director of Breast Oncology at Lifespan Cancer Institute at the Legorreta Cancer Center at Brown University in Providence, Rhode Island.

Dr. Graff serves as co-lead of the Breast Cancer Translational Research Disease Working Group at Brown University and is an Assistant Professor of Medicine at the Warren-Alpert School of Medicine. In Dr. Graff is a medical advisor to the Dr. Susan Love Foundation for Breast Cancer Research. 

Dr. Graff is board certified in Medical Oncology, Hematology, and Internal Medicine; and completed a breast oncology sub-fellowship at the University of Kansas. Dr. Graff is a PI on numerous clinical trials in addition to her work in translational research, genomics, and gender bias.

She is an award-winning writer, social media influencer, and sought-after public speaker. Dr. Graff has received the Frist Humanitarian Award for her work in the community and the Benjamin L. Sapers Memorial Award for her “passion for pedagogy, academic rigor, empathy and humanism, with profound feeling for the person as patient.”

Ultimately, Dr. Graff is passionate about connecting with her patients to provide personalized, comprehensive oncology care, advancing breast cancer research, and breast cancer prevention.

Podcast Appearances
OMBCL Shorts #1: Dr. Stephanie Graff & Her Steps For Those Newly Diagnosed MBC

Our inaugural OMBCL Shorts features Dr. Stephanie Graff talking about what she does when someone is newly diagnosed with MBC. This season, we had a 3-part series for people newly diagnosed and we couldn't resist getting her take on the topic. And we're so glad we asked!

Recent Advances, Controversies, and Emerging Trends in MBC

Over the last 20 years, advances in HER2 targeting treatments, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have prolonged survival and changed the breast cancer treatment landscape. Success leads to more questions about optimal drug sequencing, mechanisms of resistance, and how to overcome that resistance. Let’s ask Dr. Stephanie Graff to help us tackle these topics and more.

ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC?

Welcome to the second part of our post–2022-ASCO analysis of the state of affairs in the HR-positive MBC. It was not so long ago that our only options were single-agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic in selecting and sequencing treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.

ASCO 2022: When the Dust Settles, Will ADCs Change MBC?

While HER2-Low and DESTINY-Breast04 garnered most of the headlines from the ASCO 2022 in June, it was not the only reason for optimism. Our MBC Life takes a deeper dive with Dr. Stephanie Graff and Dr. Hope Rugo in this first episode of our two-part series.

Dr. Stephanie Graff: Understanding Progression

What does it mean when our cancer shows progression? And how do we know when that happens? The Our MBC Life team gets the lowdown from Dr. Stephanie L. Graff.

Searching for Unicorns: Exceptional Survivors and Responders
Previous

Nancy Lin, MD
Next

Hope Rugo, MD